SCG Cell Therapy
SCG Cell Therapy Pte. Ltd. is a clinical-stage biotechnology company headquartered in Singapore, with operations across Singapore, China and Germany, developing novel immunotherapies for infectious diseases and the cancers they cause. The company targets the most common cancer-causing infections — Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus (HBV) and Epstein-Barr virus (EBV) — and is advancing a pipeline of TCR-engineered T cell therapies, antibodies and therapeutic vaccines built on its proprietary GianTCR platform. Lead programs include SCG101, a first-in-class autologous HBV-specific TCR-T therapy targeting hepatitis B surface antigen in HBV-related hepatocellular carcinoma, and SCG142, a next-generation HPV E7-specific TCR-T therapy for HPV-associated solid tumors that received FDA IND clearance. SCG covers the full value chain from drug discovery and manufacturing through clinical development and commercialization. It is a therapeutics developer, not a software vendor, and publishes no public API, developer portal or machine-readable contract.
SCG Cell Therapy is profiled on the APIs.io network. Tagged areas include Biotechnology, Cell Therapy, Immunotherapy, Oncology, and Infectious Diseases.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Company 2
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.